相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Pennsylvania health officials reported four breakthrough measles cases in fully vaccinated residents, the first such cases in the state's 2026 outbreak. - The state's outbreak has reached 676 cases with 124 hospitalizations, making it Pennsylvania's largest measles outbreak in more than 30 years. - MMR vaccination demand surged in August, with providers administering 46,000 doses versus the typical 25,000 per month. - Two measles-associated infant deaths have been reported, though state and federal officials disagree on whether both should be linked to the outbreak.
- Lunai Bioworks announced the formation of the Pathfinder Consortium, a national academic-industry alliance designed to accelerate chemical countermeasure development to approximately three years. - The consortium targets $400 million to $1.2 billion U.S. government countermeasure programs by integrating historically fragmented chemical defense capabilities into a unified framework. - The accelerated regulatory pathway includes efficacy demonstration in yeast and cell-based systems, validation in FDA-recognized zebrafish models, two confirmatory animal studies, and a 50-person Phase I safety study. - The initiative leverages BioSymetrics' proprietary AI-enabled phenotypic platform and collaboration with nationally recognized experts from Harvard Medical School, U.S. Air Force Reserve, University of Utah, and Purdue University.
- Medtronic has established its second academic strategic partnership with CU Anschutz Innovations following a nationwide search for leading healthcare innovation institutions. - The long-term collaboration spans three University of Colorado campuses and focuses on breakthrough solutions in artificial intelligence, robotics, and sustainability. - The partnership aims to accelerate the translation of academic discoveries from lab to bedside, delivering faster patient benefits through enhanced commercialization pathways. - The formal agreement was launched at CU Anschutz on January 22, 2026, with priority research projects and advancement initiatives already identified.
- Purple Biotech presented new preclinical data at ESMO-IO 2025 demonstrating that two CAPTN-3 tri-specific antibodies, IM1240 and IM1305, achieved significant anti-tumor activity across different tumor antigens and treatment-resistant models. - IM1240 showed anti-tumor activity in PD-1-resistant patient-derived explants from NSCLC and HNSCC, with transcriptomic analysis of ~11,000 TCGA samples supporting the inclusion of the NKG2A arm in the platform design. - The new TROP2-targeting candidate IM1305 demonstrated potent tumor cell killing at low concentrations across multiple cancer types including triple-negative breast, gastric, pancreatic, and head and neck cancers. - Both antibodies utilize the CAPTN-3 platform's unique tri-specific design that engages T cells, NK cells, and tumor-associated antigens to overcome immune evasion and drug resistance mechanisms.
- Purple Biotech completed a $6 million public offering with potential for an additional $12 million through warrant exercises to fund development of its oncology therapeutic candidates. - The company is advancing three innovative cancer therapies: CAPTN-3 tri-specific antibodies, CM24 monoclonal antibody, and NT219 dual inhibitor targeting tumor immune evasion. - CM24 demonstrated clear efficacy improvements in a Phase 2 pancreatic cancer study when combined with nivolumab and chemotherapy across all endpoints. - NT219 showed anti-tumor activity in combination with cetuximab for recurrent head and neck cancer patients in Phase 1 trials.
- Emory University researchers demonstrated that psilocin, the active metabolite of psilocybin, extended human skin and lung cell lifespans by more than 50% in laboratory studies. - In aged mice equivalent to 60-65 human years, monthly psilocybin treatment for 10 months resulted in 30% increased survival compared to untreated controls. - The compound appears to delay aging by reducing oxidative stress, improving DNA repair responses, and preserving telomere length across multiple cellular pathways. - Results suggest psilocybin may have therapeutic potential beyond mental health applications, opening new avenues for anti-aging interventions in older populations.
- A comprehensive CDC VISION Network study spanning over 345,000 emergency department encounters and 111,000 hospitalizations found that 2023-2024 COVID-19 vaccines reduced critical illness risk by 48% during the first seven to 299 days after vaccination. - The vaccines demonstrated maximum protection during the first two months after vaccination, with up to 68% reduction in severe cases against critical illness, though effectiveness waned over time particularly beyond six months. - The study reinforces the importance of updated COVID-19 vaccination for vulnerable populations, especially adults 65 and older, as vaccines continued to provide strong defense against hospitalization and death throughout the study period. - Updated vaccines reduced emergency department visits by 24% and hospitalizations by 29%, offering significant protection above and beyond previous infection or vaccination during XBB and JN.1 Omicron subvariant waves.
- Semaglutide treatment slowed biological aging by approximately 9% and reduced epigenetic aging mortality risk by three years in HIV patients with lipohypertrophy over 32 weeks. - The GLP-1 receptor agonist improved visual-spatial cognitive function and delayed recall performance in people living with HIV, with effects mediated by reduced inflammation rather than weight loss. - Multiple studies presented at CROI 2025 demonstrated semaglutide's benefits beyond weight management, including enhanced gut microbiome diversity and reduced alcohol consumption in HIV patients. - Research suggests these aging and cognitive benefits may result from fundamental impacts on aging hallmarks rather than simply metabolic improvements.
- New research reveals that more than 10.6 hours of daily sedentary behavior significantly increases risk of heart failure and cardiovascular mortality, even among those meeting exercise guidelines. - A complementary study from the University of Colorado demonstrates that prolonged sitting accelerates heart aging through negative impacts on cholesterol levels and BMI, with vigorous exercise only partially offsetting these effects. - Researchers recommend replacing sitting time with physical activity, using standing desks, and incorporating at least 30 minutes of vigorous daily exercise to mitigate cardiovascular risks.
- Phase 3 EASE trial reveals birch triterpenes (Filsuvez) demonstrates sustained reduction in wound burden for epidermolysis bullosa patients over 24 months of treatment. - The topical therapy showed a favorable long-term safety profile, with most adverse events being mild-to-moderate in severity among 77.1% of participants. - Study investigator Dr. Anna Bruckner reports encouraging results for patients with dystrophic and junctional epidermolysis bullosa, with no increased risk of wound infections or squamous cell carcinoma.
